Interactions

Displaying 801 - 1000 of 1240

ARV

Drug 2

Color Code

Drug 1 dose (field_drug_1_dose)

Drug doses

ID	Title	drug 1 Sort descending	drug 1 dose	drug 1 effect	drug 2	drug 2 dose	drug 2 effect	Clinical Effects	Color	Clinical Bottom Line	Management	Alt Agents
5736	Dolutegravir NVP 121	Dolutegravir		Not studied	Nevirapine		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of dolutegravir	Contraindicated. Use alternative agents.
5705	Dolutegravir Aluminum and magnesium hydroxide antacid 90	Dolutegravir	50 mg single dose	Cmax decreased 18%, AUC decreased 26%, Cmin decreased 30%	Aluminum and magnesium hydroxide antacid	Maalox given 2 hours after dolutegravir	Not studied	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Administer dolutegravir 2 hours before or 6 hours after antacids.
5721	Dolutegravir ETR + DRV/r 106	Dolutegravir	50 mg once daily	Cmax decreased 12%, AUC decreased 25%, Cmin decreased 37%	Etravirine, Darunavir, Ritonavir	200 mg + 600 / 100 mg BID	Not studied		Green: Administer standard doses	Administer standard doses
5737	Dolutegravir Aluminum and magnesium hydroxide antacid 122	Dolutegravir	50 mg single dose	Cmax decreased 72%, AUC decreased 74%, Cmin decreased 74%	Aluminum and magnesium hydroxide antacid	Maalox given simultaneously as dolutegravir	Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of dolutegravir	Administer dolutegravir 2 hours before or 6 hours after antacids.
5706	Dolutegravir Calcium carbonate 91	Dolutegravir	50 mg single dose	Cmax decreased 37%, AUC decreased 39%, Cmin decreased 39% if taken together, fasting conditions. No significant change in dolutegravir AUC if taken 2 hours before calcium carbonate or if taken simultaneously with food.	Calcium carbonate	1200 mg	Not studied	Potential decrease in antiretroviral efficacy if taken without food	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Administer dolutegravir 2 hours before or 6 hours after calcium-containing supplements. Alternatively, administer dolutegravir simulatenously with calcium supplements and with food.
5722	Dolutegravir ATV/r 107	Dolutegravir	30 mg once daily	Cmax increased 34%, AUC increased 62%, Cmin increased 121%	Atazanavir	300 / 100 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5738	Dolutegravir ETR 123	Dolutegravir	50 mg once daily	Cmax decreased 52%, AUC decreased 71%, Cmin decreased 88%	Etravirine	200 mg once daily	Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of dolutegravir	Contraindicated. Use in combination with ATV / r or DRV / r
5707	Dolutegravir Calcium carbonate 92	Dolutegravir	50 mg single dose	Cmax decreased 37%, AUC decreased 39%, Cmin decreased 39% if taken together, fasting conditions. No significant change in dolutegravir AUC if taken 2 hours before calcium carbonate or if taken simultaneously with food.	Calcium carbonate	1200 mg	Not studied	Potential decrease in antiretroviral efficacy if taken without food	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Administer dolutegravir 2 hours before or 6 hours after calcium-containing supplements. Alternatively, administer dolutegravir simulatenously with calcium supplements and with food.
5723	Dolutegravir Omeprazole 108	Dolutegravir	50 mg single dose	No significant change	Omeprazole	40 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5739	Dolutegravir CBZ 124	Dolutegravir	50 mg once daily	Cmax decreased 33%, AUC decreased 49%, Cmin decreased 73%	Carbamazepine	300 mg BID	Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of dolutegravir	Use alternative agents. If this combination must be used in an INSTI-na•ve adult patient, adminster dolutegravir 50 mg twice daily. Do not use in cases of clinically suspected InSTI resistance. Monitor antiviral efficacy	Gabapentin, Lamotrigine, Levitiracetam, Tiagabine, Topiramate
5708	Dolutegravir Calcium carbonate 93	Dolutegravir	50 mg single dose	Cmax decreased 37%, AUC decreased 39%, Cmin decreased 39% if taken together, fasting conditions. No significant change in dolutegravir AUC if taken 2 hours before calcium carbonate or if taken simultaneously with food.	Calcium carbonate	1200 mg	Not studied	Potential decrease in antiretroviral efficacy if taken without food	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Administer dolutegravir 2 hours before or 6 hours after calcium-containing supplements. Alternatively, administer dolutegravir simulatenously with calcium supplements and with food.
5724	Dolutegravir ATV 109	Dolutegravir	30 mg once daily	Cmax increased 50%, AUC increased 91%, Cmin increased 180%	Atazanavir	400 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5709	Dolutegravir Sucralfate 94	Dolutegravir		Not studied (may decreased dolutegravir levels)	Sucralfate		Not studied	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Administer dolutegravir 2 hours before or 6 hours after sucralfate
5725	Dolutegravir Prednisone 110	Dolutegravir	50 mg once daily	Cmax increased 6%, AUC increased 11%, Cmin increased 17%	Prednisone	60 mg daily with taper	Not studied		Green: Administer standard doses	Administer standard doses
5710	Dolutegravir Multivitamin 95	Dolutegravir	50 mg single dose	Cmax decreased 35%, AUC decreased 33%, Cmin decreased 32%	Multivitamin	One-A-Day given simultaneously with dolutegravir	Not studied	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Administer dolutegravir 2 hours before or 6 hours after taking medications containing polyvalent cations.
5726	Dolutegravir DRV/r 111	Dolutegravir	30 mg once daily	Cmax decreased 11%, AUC decreased 22%, Cmin decreased 38%	Darunavir	600 / 100 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5711	Dolutegravir Iron 96	Dolutegravir	50 mg single dose	Cmax decreased 57%, AUC decreased 54%, Cmin decreased 56% when administered simultaneously with ferrous fumarate, fasting conditions. No significant change in dolutegravir Cmax or AUC if given simultaneously with ferrous fumarate, with food or if given 2 hours after ferrous fumarate.	Ferrous fumarate	324 mg	Not studied	Potential decrease in antiretroviral efficacy if given with iron.	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Administer dolutegravir 2 hours before or 6 hours after taking medications containing polyvalent cations. Alternatively, administer dolutegravir simulatenously with iron supplements and with food.
5727	Dolutegravir SOF/VEL 112	Dolutegravir	50 mg once daily	Not studied	Sofosbuvir / Velpatasvir	400 / 100 mg daily	Sofosbuvir Cmax decreased 12%, AUC decreased 8%. No significant change in sofosbuvir metabolite GS-331007. Velpatasvir Cmax decreased 6%, AUC decreased 9%, Cmin decreased 12%.		Green: Administer standard doses	Administer standard doses
5712	Dolutegravir RFB 97	Dolutegravir	50 mg once daily	Cmax increased 16%, AUC decreased 5%, Cmin decreased 30%	Rifabutin	300 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
5728	Dolutegravir INH 113	Dolutegravir	50 mg once daily	AUC decreased 46%, Cmin decreased 74%	Isoniazid	15 mg / kg + rifapentine 900 mg once weekly	INH AUC increased 67-92% in 2 / 4 subjects. Rifapentine no significant change.	Potential for increased adverse effects of isoniazid (flu-like symptoms, nausea, vomiting, and fever)	Red: Avoid combination	Do not coadminister: Increased levels of izoniazid and reduced levels of dolutegravir	Use alternative agents
5713	Dolutegravir RPV 98	Dolutegravir	50 mg once daily	Cmax increased 13%, AUC increased 12%, Cmin increased 22%	Rilpivirine	25 mg once daily	Cmax increased 10%, AUC increased 6%, Cmin increased 21%		Green: Administer standard doses	Administer standard doses
5729	Dolutegravir Dalfampridine 114	Dolutegravir		Not studied	Dalfampridine		Not studied	Potential for increased dalfampridine toxicity	Red: Avoid combination	Do not coadminister: Potential for increased levels of dalfampridine	Contraindicated. Use alternative agents.
5714	Dolutegravir TDF 99	Dolutegravir	50 mg once daily	Cmax decreased 3%, AUC increased 1%, Cmin decreased 8%	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increased 9%, AUC increased 12%, Cmin increased 19%		Green: Administer standard doses	Administer standard doses
5730	Dolutegravir Dofetilide 115	Dolutegravir		Not studied	Dofetilide		Not studied	Potential for increased dofetilide toxicity	Red: Avoid combination	Do not coadminister: Potential for increased levels of dofetilide	Contraindicated. Use alternative agents.
5747	Elvitegravir Methadone 132	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Not reported	Methadone	80-120 mg daily	No significant change in R-methadone or S-methadone		Green: Administer standard doses	Administer standard doses
5763	Elvitegravir Iron 148	Elvitegravir			Ferrous sulfate			Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased elvitegravir efficacy	Separate elvitegravir / cobicistat from medications containing polyvalent cations by at least 2 hours.
5779	Elvitegravir Edoxaban 164	Elvitegravir			Edoxaban			Potential for increased risk of bleeding	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of edoxaban	Edoxaban 30 mg once daily if using for DVT / PE. No adjustment needed for stroke prevention in persons with atrial fibrillation.
5795	Elvitegravir Ethosuximide 180	Elvitegravir			Ethosuximide			Potential for increased anticonvulsant effects	Green: Administer standard doses	Administer standard doses	Monitor for ethosuximide adverse effects
5811	Elvitegravir Mometasone 196	Elvitegravir			Mometasone			Potential for increased risk of adrenal insufficiency and Cushing's syndrome	Red: Avoid combination	Do not coadminister: Potential for increased levels of mometasone	Use alternative agents	Beclomethasone, prednisone, prednisolone
5827	Elvitegravir Ticagrelor 212	Elvitegravir			Ticagrelor			Potential for increased risk of bleeding	Red: Avoid combination	Do not coadminister: Potential for increased levels of ticagrelor	Avoid combination and use alternative antiplatelet agent.
5843	Elvitegravir Budesonide 228	Elvitegravir			Budesonide			Potential for increased risk of adrenal insufficiency and Cushing's syndrome	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents	Beclomethasone
5859	Elvitegravir Everolimus 244	Elvitegravir			Everolimus			Increased everolimus effects (e.g. excessive immunosuppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor everolimus levels and adjust dose as indicated
5875	Elvitegravir Nicardipine 260	Elvitegravir			Nicardipine			Potential for increased risk of nicardipine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor ECG
5891	Elvitegravir Itraconazole 276	Elvitegravir			Itraconazole			Potential for increased adverse effects from both elvitegravir and itraconazole	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Monitor itraconazole concentrations. If coadministering itraconazole dose should not exceed 200 mg daily unless guided by concentrations.
5748	Elvitegravir Omeprazole 133	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	If omeprazole given 2 hours before EVG, Cmax increased 16%, AUC increased 10%, Cmin increased 13%. If given 12h after, no significant change.	Omeprazole	20 mg given 2 hours before or 12 hours after elvitegravir	Not reported		Green: Administer standard doses	Administer standard doses
5764	Elvitegravir Sucralfate 149	Elvitegravir			Sucralfate			Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased elvitegravir efficacy	Separate elvitegravir / cobicistat from sucralfate by at least 2 hours.
5780	Elvitegravir Iloperidone 165	Elvitegravir			Iloperidone			Potential for increased risk of iloperidone adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of iloperidone	Decrease iloperidone dose by 50%
5796	Elvitegravir G/P 181	Elvitegravir		AUC increased 47%	Glecaprevir / Pibrentasvir		Glecaprevir AUC increased 3 fold; PIB AUC increased 57%	Potential increase in GLEC / PIB toxicity	Green: Administer standard doses	Administer standard doses
5812	Elvitegravir Pimozide 197	Elvitegravir			Pimozide			Potential serious or life-threatening reactions such as cardiac arrhythmia.	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Contraindicated. Use alternative agents.
5828	Elvitegravir Vorapaxar 213	Elvitegravir			Vorapaxar			Potential for increased risk of bleeding	Red: Avoid combination	Do not coadminister: Potential for increased levels of vorapaxar	Avoid combination and use alternative antiplatelet agent
5844	Elvitegravir Oxcarbazepine 229	Elvitegravir			Oxcarbazepine			Potential decrease in antiretroviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative agents
5860	Elvitegravir Prednisone 245	Elvitegravir			Prednisone			Potential for increased risk of adrenal insufficiency and Cushing's syndrome, but PK / PD less affected by strong CYP3A4 inhibitors	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor for adrenal insufficiency and Cushing's syndrome
5876	Elvitegravir Nifedipine 261	Elvitegravir			Nifedipine			Potential for increased risk of nifedipine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor ECG
5892	Elvitegravir Eluxadoline 277	Elvitegravir			Eluxadoline			Potential for increased risk of eluxadoline adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Monitor response and titrate according to efficacy and adverse effects.
5749	Elvitegravir Famotidine 134	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	No significant change in AUC or Cmax when administered 12 hours apart or if administered simultaneously	Famotidine	40 mg given 12 hours after EVG or 40 mg given simultaneously with EVG	Not reported		Green: Administer standard doses	Administer standard doses
5765	Elvitegravir Amitriptyline 150	Elvitegravir			Amitriptyline			Potential for increased risk of amitriptyline adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of amitriptyline	If coadministering initiate amitriptyline at lowest dose. Monitor response and titrate according to efficacy and adverse effects.
5781	Elvitegravir Imipramine 166	Elvitegravir			Imipramine			Potential for increased risk of imipramine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of imipramine	If coadministering initiate imipramine at lowest dose. Monitor response and titrate according to efficacy and adverse effects.
5797	Elvitegravir Dapagliflozin / Saxagliptin 182	Elvitegravir		Not reported	Dapagliflozin / Saxagliptin	saxagliptin 5 mg	Not reported	Potential for increased saxagliptin adverse effects	Red: Avoid combination	Do not coadminister: Increased levels of saxagliptin	Use alternative agents
5813	Elvitegravir Silodosin 198	Elvitegravir			Silodosin			Potential for increased silodosin adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of silodosin	Contraindicated. Use alternative agents.
5829	Elvitegravir Clopidogrel 214	Elvitegravir			Clopidogrel			Potential reduction of antiplatelet activity	Red: Avoid combination	Do not coadminister: Potential for reduced levels of clopidogrel	Use alternative agents
5845	Elvitegravir Testosterone 230	Elvitegravir			Testosterone			Potential for increased risk of testosterone adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Adjust testosterone dose based on clinical effects and endogenous hormone concentrations.
5861	Elvitegravir Dronedarone 246	Elvitegravir			Dronedarone			Potential for increased risk of dronedarone adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor for dronedarone toxicity. Consider therapeutic drug monitoring and ECG.
5877	Elvitegravir Verapamil 262	Elvitegravir			Verapamil			Potential for increased risk of verapamil adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor ECG
5893	Elvitegravir Dexamethasone 278	Elvitegravir			Dexamethasone			Potential loss of antiviral efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Monitor viral load if extended dexamethasone use. Consider alternative corticosteroid for long-term use.	Beclomethasone, prednisone, prednisolone
5750	Elvitegravir RFB 135	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Cmax decreased 9%, AUC decreased 21%, Cmin decreased 67%	Rifabutin	150 mg every other day	No significant change in rifabutin Cmin, AUC, or Cmax. 25-O-desacetylrifabutin metabolite Cmax increased 384%, AUC increased 625%, Cmin increased 394% as compared to 300 mg rifabutin alone.	Increased rifabutin effects, potential loss of antiretroviral activity	Red: Avoid combination	Do not coadminister: Increased levels of rifabutin, reduced levels of elvitegravir	Use alternative agents
5766	Elvitegravir Aripiprazole 151	Elvitegravir		Not reported	Aripiprazole			Potential for increased risk of aripiprazole adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of aripiprazole	Administer 25% of usual aripiprazole dose and titrate based on efficacy and adverse effects
5782	Elvitegravir Nortriptyline 167	Elvitegravir			Nortriptyline			Potential for increased risk of nortriptyline adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of nortriptyline	If coadministering initiate nortriptyline at lowest dose. Monitor response and titrate according to efficacy and adverse effects.
5798	Elvitegravir Avanafil 183	Elvitegravir			Avanafil			Potential for increased risk avanafil adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased level of avanafil	Contraindicated. Use alternative agents.
5814	Elvitegravir Simeprevir 199	Elvitegravir			Simeprevir			Potential for increased simeprevir toxicity	Red: Avoid combination	Do not coadminister: Potential for increased levels of simeprevir	Use alternative agents
5830	Elvitegravir RIF 215	Elvitegravir			Rifampin			Expected significant decreased in elvitegravir, cobicistat. Potential decreased antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Contraindicated. Use alternative agents.
5846	Elvitegravir Betrixaban 231	Elvitegravir			Betrixaban			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Administer single dose of betrixaban 80 mg, followed by betrixaban 40 mg once daily
5862	Elvitegravir Warfarin 247	Elvitegravir			Warfarin			Potential over or under anticoagulation	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
5878	Elvitegravir Amiodarone 263	Elvitegravir			Amiodarone			Potential for increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for amiodarone toxicity. Consider therapeutic drug monitoring and ECG.
5894	Elvitegravir Nefazodone 279	Elvitegravir			Nefazodone			Potential for increased risk of nefazodone adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents
5751	Elvitegravir CBZ 136	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Cmax decreased 45%, AUC decreased 69%, Cmin decreased 97%	Carbamazepine	200 mg BID	Cmax increased 40%, AUC increased 43%, Cmin increased 51%. Epoxide metabolite (pharmacologically active) Cmax decreased 73%, AUC decreased 35%, and Cmin decreased 41%.	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of elvitegravir	Contraindicated. Use alternative agents.
5767	Elvitegravir Brexpiprazole 152	Elvitegravir			Brexpiprazole			Potential for increased risk of brexpiprazole adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of aripiprazole	Administer 25% of usual bexpiprazole dose and titrate based on efficacy and adverse effects
5783	Elvitegravir Paroxetine 168	Elvitegravir			Paroxetine			Potential for increased risk of paroxetine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of paroxetine	If coadministering initiate paroxetine at lowest dose. Monitor response and titrate dose according to efficacy and adverse effects.	Sertraline
5799	Elvitegravir Lomitapide 184	Elvitegravir			Lomitapide			Potential for increased risk of elevated transaminases	Red: Avoid combination	Do not coadminister: Potential for increased level of lomitapide	Contraindicated. Use alternative agents.
5815	Elvitegravir Simvastatin 200	Elvitegravir			Simvastatin			Potential for increased simvastatin effects (e.g. myopathy, rhabdomyolysis)	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Contraindicated. Use alternative agents.	Atorvastatin Pravastatin
5831	Elvitegravir Phenobarbital 216	Elvitegravir			Phenobarbital			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Contraindicated. Use alternative agents.
5847	Elvitegravir Metoprolol 232	Elvitegravir			Metoprolol			Potential for increased risk of metoprolol adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider alternative agents. If coadministering initiate beta-blocker at low dose and titrate to clinical effect while monitoring for adverse effects.	Atenolol, labetalol, nadolol, sotalol
5863	Elvitegravir Isavuconazole 248	Elvitegravir			Isavuconazole				Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor isavuconazole concentrations and assess virologic response.
5879	Elvitegravir Disopyramide 264	Elvitegravir			Disopyramide			Potential for increased risk of disopyramide adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for disopyramide toxicity. Consider therapeutic drug monitoring and ECG
5895	Elvitegravir Erythromycin 280	Elvitegravir			Erythromycin				Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents	Azithromycin
5752	Elvitegravir EE/NGM 137	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Not reported	Ethinyl estradiol / Norgestimate	0.18 / 0.215 / 0.250 mg NGM once daily, 0.025 mg EE once daily	Ethinyl estradiol Cmax decrease 6%, AUC decrease 25%, Cmin decrease 44%; Norgestimate Cmax increased 108%, AUC increased 126%, Cmin increased 167%	Potential for increased norgestimate effects (e.g. insulin resistance, dyslipidemia, acne, venous thrombosis); Potential decreased ethinyl estradiol effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Additional or alternative contraception should be considered.
5768	Elvitegravir Beclomethasone 153	Elvitegravir			Beclomethasone			Potential for increased risk of corticosteroid adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of Beclomethasone	If coadministering, initiate lower dose and monitor for corticosteroid adverse effects
5784	Elvitegravir Perphenazine 169	Elvitegravir			Perphenazine			Potential for increased risk of perphenazine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of perphenazine	Initiate lowest starting dose or decrease current dose of antipsychotic. Monitor efficacy and adverse effects.
5800	Elvitegravir Alfuzosin 185	Elvitegravir			Alfuzosin			Potential for increased alfuzosin adverse effects (e.g. hypotension)	Red: Avoid combination	Do not coadminister: Potential for increased levels of alfuzosin	Contraindicated. Use alternative agents.
5816	Elvitegravir Triamcinolone 201	Elvitegravir			Triamcinolone			Potential for increased risk of adrenal insufficiency and Cushing's syndrome	Red: Avoid combination	Do not coadminister: Potential for increased levels of triamcinolone	Do not coadminister if triamcinolone is used for local injection.	Beclomethasone
5832	Elvitegravir Phenytoin 217	Elvitegravir			Phenytoin			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Contraindicated. Use alternative agents.
5848	Elvitegravir Timolol 233	Elvitegravir			Timolol			Potential for increased risk of timolol adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider alternative agents. If coadministering initiate beta-blocker at low dose and titrate to clinical effect while monitoring for adverse effects.	Atenolol, labetalol, nadolol, sotalol
5864	Elvitegravir Clorazepate 249	Elvitegravir			Clorazepate			Potential for increased risk of sedative-hypnotic adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering start with low dose and titrate accordingly. Monitor for side effects.	Lorazepam, Oxazepam, Temazepam
5880	Elvitegravir Flecainide 265	Elvitegravir			Flecainide			Potential for increased risk of flecainide adverse effects (eg, cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for flecainide toxicity. Consider therapeutic drug monitoring and ECG
5753	Elvitegravir LDV/SOF 138	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	AUC increased 11%, Cmin increased 46%	Ledipasvir / Sofosbuvir	90 / 400 mg once daily	Ledipasvir Cmax increased 65%, AUC increased 79%, Cmin increased 93%; Sofosbuvir Cmax increased 28%, AUC increased 47%; Sofosbuvir metabolite Cmax increased 29%, AUC increased 48%, Cmin increased 66%%	Potential increase in ledipasvir toxicity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Manufacturer does not recommend co-administration of ledipasvir / sofosbuvir with Stribild due to interaction with tenofovir disoproxil fumarate. May coadminister with Genvoya.
5769	Elvitegravir Bosentan 154	Elvitegravir			Bosentan			Potential for increased risk of bosentan adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of bosentan	If patient has been on elvitegravir / cobicistat for more than 10 days, start with bosentan dose of 62.5 mg daily or every other day. If patient is currently on bosentan and requires use of elvitegravir / cobicistat, stop bosentan for at least 36 hours prior to initiating ART. Wait 10 days and then resume bosentan starting with 62.5 mg daily or every other day.
5785	Elvitegravir Pimavanserin 170	Elvitegravir			Pimavanserin			Potential for increased risk of nefazodone adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of pimavanserin	Reduce pimavanserin dose to 10 mg
5801	Elvitegravir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 186	Elvitegravir			Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir			Potential for increased AUC of HCV agents	Red: Avoid combination	Do not coadminister: Potential for increased levels of antivirals	Use alternative agents
5817	Elvitegravir Triazolam 202	Elvitegravir			Triazolam			Potential for increased triazolam effects (e.g. prolonged sedation, altered mental status, respiratory depression)	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Contraindicated. Use alternative agents.
5833	Elvitegravir Eslicarbazepine 218	Elvitegravir			Eslicarbazepine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Contraindicated. Use alternative agents.
5849	Elvitegravir Quetiapine 234	Elvitegravir			Quetiapine			Potential for increased risk of quetiapine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider alternative ARV therapy. For patients currently on elvitegravir / cobicistat: initiate quetiapine at lowest dose. Titrate accordingly and monitor for adverse effects. If patient already on quetiapine and requiring new elvitegravir / cobicistat: reduce queitapine to 1 / 6 of original dose before coadministering. Monitor efficacy and adverse effects.
5865	Elvitegravir Diazepam 250	Elvitegravir			Diazepam			Potential for increased risk of sedative-hypnotic adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering start with low dose and titrate accordingly. Monitor for side effects.	Lorazepam, Oxazepam, Temazepam
5881	Elvitegravir Lidocaine 266	Elvitegravir			Lidocaine			Potential for increased risk of lidocaine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for lidocaine toxicity. Consider therapeutic drug monitoring and ECG if used systemically.
5754	Elvitegravir SOF/VEL 139	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Cmax and AUC decreased 7%; Cmin decreased 3%	Sofosbuvir / Velpatasvir	400 / 100 mg once daily	Velpatasvir Cmax increased 5%, AUC increased 19%, Cmin increased 37%; Sofosbuvir Cmax increased 1%, AUC increased 24%; Sofosbuvir metabolite Cmax increased 13%, AUC increased 35%, Cmin increased 45%	Stribild is coformulated with tenofovir disoproxil fumarate and TDF levels are increased by sofosbuvir / velpatasvir.	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	May coadminister with caution. Monitor for adverse reactions associated with TDF
5770	Elvitegravir Bupropion 155	Elvitegravir			Bupropion			Potential for increased risk of bupropion adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of bupropion	If coadministering initiate bupropion at lowest dose. Monitor response and titrate according to efficacy and adverse effects.
5786	Elvitegravir Risperidone 171	Elvitegravir			Risperidone			Potential for increased risk of risperidone adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of risperidone	Initiate lowest starting dose or decrease current dose of antipsychotic. Monitor efficacy and adverse effects.
5802	Elvitegravir EBR/GZR 187	Elvitegravir		No significant change	Elbasvir / Grazoprevir		Elbasvir Cmax increased 91%, AUC increased 118%; Grazoprevir Cmax increased 359%, AUC increased436%	Potential for increased AUC of HCV agents	Red: Avoid combination	Do not coadminister: Potential for increased levels of antivirals	Use alternative agents
5818	Elvitegravir Lurasidone 203	Elvitegravir			Lurasidone			Potential serious or life-threatening reactions	Red: Avoid combination	Do not coadminister: potential toxicity	Contraindicated. Use alternative agents.
5834	Elvitegravir St. John's Wort (Hypericum perforatum) 219	Elvitegravir			St. John's Wort			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Contraindicated. Use alternative agents.
5850	Elvitegravir Fluvoxamine 235	Elvitegravir			Fluvoxamine			Potential decreased elvitegravir effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Consider using alternative antidepressant	Sertraline
5866	Elvitegravir Estazolam 251	Elvitegravir			Estazolam			Potential for increased risk of sedative-hypnotic adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering start with low dose and titrate accordingly. Monitor for side effects.	Lorazepam, Oxazepam, Temazepam
5882	Elvitegravir Mexiletine 267	Elvitegravir			Mexiletine			Potential for increased risk of mexiletine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for mexiletine toxicity. Consider therapeutic drug monitoring and ECG
5755	Elvitegravir SOF/VEL/VOX 140	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Cmax decreased 21%; AUC decreased 6%; Cmin increased 32%	Sofosbuvir / Velpatasvir / Voxilaprevir	400 / 100 / 100 mg plus 100 mg voxilaprevir	Voxilaprevir Cmax increased 92%; AUC increased 171%; Cmin increased 350%. Velpatasvir AUC increased 16%; Cmin increased 46%. Sofosbuvir Cmax increased 27%; AUC increased 22%		Green: Administer standard doses	Administer standard doses	If coadministering with Stribild, monitor for TDF related adverse effects. Consider monitoring for hepatotoxicity when coadministering with either Stribild or Genvoya
5771	Elvitegravir Buspirone 156	Elvitegravir			Buspirone			Potential for increased risk of buspirone adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of buspirone	If coadministering start with low dose buspirone and titrate accordingly. A dose reduction may be required. Monitor for side effects.	Lorazepam, Oxazepam, Temazepam
5787	Elvitegravir Sildenafil 172	Elvitegravir			Sildenafil			Potential for increased sildenafil effects (eg, hypotension, priapism, visual disturbances)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of sildenafil.	For erectile dysfunction, initiate sildenafil 25 mg every 48 hours and monitor for adverse effects. Manufacturer recommends not to exceed dose of 25 mg every 48 hours. Do not coadminister if using sildenafil for pulmonary arterial hypertension.
5803	Elvitegravir Dihydroergotamine 188	Elvitegravir			Dihydroergotamine			Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)	Red: Avoid combination	Do not coadminister: Potential for increased levels of dihydroergotamine	Contraindicated. Use alternative agents.
5819	Elvitegravir Lumateperone 204	Elvitegravir			Lumateperone			Potential for increased risk of lumateperone adverse effects	Red: Avoid combination	Do not coadminister: potential toxicity	Use alternative agents
5835	Elvitegravir RPT 220	Elvitegravir			Rifapentine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Use alternative agents
5851	Elvitegravir Dabigatran 236	Elvitegravir			Dabigatran			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Dosing depends on indication and renal function. For DVT and PE, avoid co-administration if CrCL < 50 mL / min. For stroke and embolism prevention in persons with atrial fibrillation, do not coadminister in severe renal insufficiency (CrCL< 30mL / min) and consider dose reduction to 75 mg twice daily if CrCL between 30 - 50mL / min
5867	Elvitegravir Flurazepam 252	Elvitegravir			Flurazepam			Potential for increased risk of sedative-hypnotic adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering start with low dose and titrate accordingly. Monitor for side effects.	Lorazepam, Oxazepam, Temazepam
5883	Elvitegravir Propafenone 268	Elvitegravir			Propafenone			Potential for increased risk of propafenone adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor for propafenone toxicity. Consider therapeutic drug monitoring and ECG
5740	Elvitegravir Desipramine 125	Elvitegravir	150 mg cobicistat once daily (no elvitegravir)	Not reported	Desipramine	50 mg single dose	Cmax increased 24%, AUC increased 65%	Increased desipramine effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of desipramine	If coadministering, initiate low dose desipramine and titrate according to efficacy and adverse effects.
5756	Elvitegravir SOF/VEL 141	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Cmax decreased 13%; AUC decreased 6%; Cmin increased 8%	Sofosbuvir / Velpatasvir	400 / 100 mg once daily	Velpatasvir Cmax increased 30%, AUC increased 50%, Cmin increased 60%; Sofosbuvir Cmax increased 23%, AUC increased 37%; Sofosbuvir metabolite Cmax increased 29%, AUC increased 48%, Cmin increased 58%	Stribild is coformulated with tenofovir disoproxil fumarate and TDF levels are increased by sofosbuvir / velpatasvir.	Green: Administer standard doses	Administer standard doses	Monitor TDF-related adverse reactions
5772	Elvitegravir Calcifediol 157	Elvitegravir			Calcifediol				Yellow: Adjust dosing	Adjust dosing to avoid increased levels of calcifediol	Monitor serum 25-hydroxyvitamin D, intact PTH, and serum Ca concentrations. Adjust dose as needed.
5788	Elvitegravir Tadalafil 173	Elvitegravir			Tadalafil			Potential for increased tadalafil effects (e.g. hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of tadalafil	For erectile dysfunction, initiate tadalafil 5 mg dose and do not exceed 10 mg every 72 hours. Monitor adverse effects. For patients taking a protease inhibitor (stable > 7 days) requiring tadalafil for pulmonary arterial hypertension initiate 20 mg once daily and increase to 40 mg once daily based on tolerability. Patients currently on tadalafil who require a PI should stop tadalafil ³24 hours before PI initiation, take the PI for 7 days, then resume tadalafil at 20 mg. Maximum recommended daily dose for treatment of BPH is 2.5 mg daily.
5804	Elvitegravir Ergotamine 189	Elvitegravir			Ergotamine			Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Contraindicated. Use alternative agents.
5820	Elvitegravir Dofetilide 205	Elvitegravir			Dofetilide			Potential for increased risk of dofetilide adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of dofetilide	Use alternative agents
5836	Elvitegravir LNG 221	Elvitegravir			Levonorgestrel			Potential increase in levonorgestrel adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Additional or alternative contraception should be considered.
5852	Elvitegravir Dutasteride 237	Elvitegravir			Dutasteride			Potential for increased risk of dutasteride adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering adjust dutasteride dose based on clinical effects and endogenous hormone concentrations.
5868	Elvitegravir Zolpidem 253	Elvitegravir			Zolpidem			Potential for increased risk of sedative-hypnotic adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering start with low dose and titrate accordingly. Monitor for side effects.	Lorazepam, Oxazepam, Temazepam
5884	Elvitegravir Sirolimus 269	Elvitegravir			Sirolimus			Increased sirolimus adverse effects (increased immunosuppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
5741	Elvitegravir Digoxin 126	Elvitegravir	150 mg cobicistat once daily (without elvitegravir)	Not reported	Digoxin	0.5 mg single dose	Cmax increased 41%, AUC increased 8%	Potential for increased digoxin adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, use with caution. Monitor levels and digoxin adverse effects
5757	Elvitegravir LDV/SOF 142	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Cmax decreased 12%, AUC increased 2%, Cmin increased 36%	Ledipasvir / Sofosbuvir	90 / 400 mg once daily	Ledipasvir Cmax increased 63%, AUC increased 78%, Cmin increased 91%; Sofosbuvir Cmax increased 33%, AUC increased 36%; Sofosbuvir metabolite Cmax increased 33%, AUC increased 44%, Cmin increased 53%	Potential increase in ledipasvir toxicity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Manufacturer does not recommend co-administration of ledipasvir / sofosbuvir with Stribild due to interaction with tenofovir disoproxil fumarate. If coadministering, monitor for tenofovir renal toxicity. May coadminister with Genvoya.
5773	Elvitegravir Cariprazine 158	Elvitegravir			Cariprazine			Potential for increased risk of cariprazine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of cariprazine	If patient is receiving EVG / c, administer cariprazine 1.5 mg on Day 1 and Day 3, with no dose given on Day 2. From Day 4 onward, administer cariprazine 1.5 mg daily. Dose can be increased to a maximum dose of 3 mg daily. If EVG / c is withdrawn, cariprazine dose may need to be increased. If patient is receiving cariprazine 3 mg or 6 mg daily, reduce cariprazine dose by half. For patients taking cariprazine 4.5 mg daily, the dose should be reduced to 1.5 mg or 3 mg daily. For patients taking cariprazine 1.5 mg daily, change to 1.5 mg every other day. If EVG / c is withdrawn, cariprazine dose may need to be increased.
5789	Elvitegravir Terazosin 174	Elvitegravir			Terazosin			Potential for increased terazosin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of terazosin	Initiate low dose terazosin and titrate dose according to efficacy and adverse effects.
5805	Elvitegravir Fluticasone 190	Elvitegravir			Fluticasone			Potential for increased risk of adrenal insufficiency and Cushing's syndrome	Red: Avoid combination	Do not coadminister: Potential for increased levels of fluticasone	Use alternative agents	Beclomethasone
5821	Elvitegravir Eplerenone 206	Elvitegravir			Eplerenone			Potential for increased risk of eplerenone adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of eplerenone	Contraindicated. Use alternative agents.
5837	Elvitegravir Ethinyl estradiol / Drospirenone 222	Elvitegravir			Ethinyl estradiol / Drospirenone			Potential for increased drospirenone effects (hyperkalemia); Potential decreased ethinyl estradiol effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Additional or alternative contraception should be considered. If using, monitor potassium.
5853	Elvitegravir Ciclesonide 238	Elvitegravir			Ciclesonide			Potential for increased risk of adrenal insufficiency and Cushing's syndrome	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering assess risk and benefit	Beclomethasone
5869	Elvitegravir Ziprasidone 254	Elvitegravir			Ziprasidone			Potential for increased risk of ziprasidone adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering start with low dose and titrate accordingly. Monitor for side effects.
5885	Elvitegravir Tacrolimus 270	Elvitegravir			Tacrolimus			Increased tacrolimus adverse effects (increased immunosuppression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
5742	Elvitegravir Atorvastatin 127	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	AUC decreased 8%	Atorvastatin	10 mg single dose	Cmax increased 132%; AUC increased 160%.	Potential for increased atorvastatin adverse effects (e.g. myopathy)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atorvastain	Initiate with lowest Potential dose of atorvastatin. Titrate carefully while monitoring for adverse effects. Do not exceed 20 mg of atorvastatin daily.
5758	Elvitegravir Aluminum and magnesium hydroxide antacid 143	Elvitegravir	Not reported	AUC decreased 40-50% when administered simultaneously with antacid; AUC decreased 15-20% when administered 2 hours before or after antacid. No change in AUC if separated by 4-hour interval.	Aluminum and magnesium hydroxide antacid	Not reported	Not reported	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased elvitegravir efficacy	Administer elvitegravir at least 2 hours before or at least 6 hours after supplements that contain polyvalent cations.
5774	Elvitegravir Clarithromycin 159	Elvitegravir			Clarithromycin				Yellow: Adjust dosing	Adjust dosing to avoid increased levels of clarithromycin	No dose adjustment necessary if patients CrCl > 60 mL / min. Reduce clarithromycin dose by 50% if CrCl is between 50-60 mL / min. Do not coadminster if CrCl > 50 mL / min.	Azithromycin
5790	Elvitegravir Thioridazine 175	Elvitegravir			Thioridazine			Potential for increased risk of thioridazine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of thioridazine	Initiate lowest starting dose or decrease current dose of antipsychotic. Monitor efficacy and adverse effects.
5806	Elvitegravir HMG-CoA Reductase Inhibitors 191	Elvitegravir			Lovastatin			Potential for increased lovastatin effects (e.g. myopathy, rhabdomyolysis)	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Contraindicated. Use alternative agents.	Atorvastatin Pravastatin
5822	Elvitegravir Flibanserin 207	Elvitegravir			Flibanserin			Potential for increased risk of flibanserin adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of flibanserin	Use alternative agents
5838	Elvitegravir Rivaroxaban 223	Elvitegravir			Rivaroxaban			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative anticoagulant
5854	Elvitegravir Voriconazole 239	Elvitegravir			Voriconazole				Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering assess risk and benefit. Consider monitoring voriconaozle concentrations.
5870	Elvitegravir Fluoxetine 255	Elvitegravir			Fluoxetine			Potential for increased risk of fluoxetine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering start with lowest fluoxetine dose. Monitor response and titrate dose according to efficacy and adverse effects	Sertraline
5886	Elvitegravir CsA 271	Elvitegravir		Not reported	Cyclosporine			Potential for increased cyclosporine toxicity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
5743	Elvitegravir Rosuvastatin 128	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat single dose	No significant change	Rosuvastatin	10 mg single dose	Cmax increased 89%, AUC increased 38%, Cmin increased 43%	Potential for increased risk of rosuvastatin adverse effects (e.g. myopathy)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rosuvastatin	Initiate rosuvastatin at lowest dose and titrate carefully. Monitor for adverse effects.
5759	Elvitegravir Pitavastatin 144	Elvitegravir			Pitavastatin			Potential for increased risk of pitavastatin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of pitavastatin	Initiate pitavastatin at lowest dose and titrate carefully. Monitor for adverse effects.
5775	Elvitegravir Colchicine 160	Elvitegravir			Colchicine			Potential for increased risk of colchicine adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of colchicine	If coadministering for treatment of gout flares use 0.6 mg single dose followed by 0.3 mg single dose 1h later and do not repeat for at least 3 days. If coadministering for prophylaxis of gout flares adjust based on original regimen (e.g. reduce 0.6 mg BID to 0.3 mg once daily, reduce 0.6 mg once daily to 0.3 mg every other day). If coadministering for FMF, maximum daily dose is 0.6 mg. Do not coadminister in hepatic or renal impairment.
5791	Elvitegravir Trazodone 176	Elvitegravir			Trazodone			Potential for increased trazodone adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of trazodone	If coadministering initiate trazodone at lowest dose. Monitor response and titrate according to efficacy, adverse effects.
5807	Elvitegravir Methylergonovine 192	Elvitegravir			Methylergonovine			Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)	Red: Avoid combination	Do not coadminister: Potential for increased levels of methylergonovine	Contraindicated. Use alternative agents.
5823	Elvitegravir Ivabradine 208	Elvitegravir			Ivabradine			Potential for increased risk of ivabradine adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of ivabradine	Contraindicated. Use alternative agents.
5839	Elvitegravir Apixaban 224	Elvitegravir			Apixaban			Potential for increased risk of bleeding	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider avoiding combination and using alternative anticoagulant. If coadministering, reduce apixaban dose by 50% in patients who require 5-10 mg twice daily. Do not coadminister in persons who require apixaban 2.5mg twice daily.
5855	Elvitegravir Prednisolone 240	Elvitegravir			Prednisolone			Potential for increased risk of adrenal insufficiency and Cushing's syndrome, but PK / PD less affected by strong CYP3A4 inhibitors	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering for systemic use, monitor for adrenal insufficiency and Cushing's syndrome. Do not coadminister if prednisolone needed for local injections.
5871	Elvitegravir Lofexidine 256	Elvitegravir			Lofexidine			Potential for increased risk of lofexidine adverse effects (e.g. orthostasis and bradycardia)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor blood pressure, heart rate, and dizziness.
5887	Elvitegravir Ketoconazole 272	Elvitegravir			Ketoconazole			Potential for increased adverse effects from both elvitegravir and ketoconazole	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, ketoconazole dose should not exceed 200 mg daily.
5744	Elvitegravir Buprenorphine / naloxone 129	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Not reported	Buprenorphine / naloxone	16-24 mg once daily	Buprenorphine Cmax increased 12%, AUC increased 35%, Cmin increased 66%. Norbuprenorphine metabolite Cmax increased 24%, AUC increased 42%, Cmin increased 57%	Potential for increased risk of sedation and decreased cognition	Green: Administer standard doses	Administer standard doses	If using, monitor closely for excess sedation and cognitive effects
5760	Elvitegravir Saxagliptin 145	Elvitegravir			Saxagliptin			Potential for increased saxagliptin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of saxagliptin	Limit saxagliptin dose to 2.5 mg once daily
5776	Elvitegravir Daclatasvir 161	Elvitegravir			Daclatasvir				Yellow: Adjust dosing	Adjust dosing to avoid increased levels of daclatasvir	Decrease daclatasvir dose to 30 mg daily
5792	Elvitegravir Vardenafil 177	Elvitegravir			Vardenafil			Potential for increased vardenafil effects (e.g. hypotension, priapism)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of vardenafil	Initiate vardenafil 2.5 mg every 72 hours and monitor for adverse effects
5808	Elvitegravir Methylprednisolone 193	Elvitegravir			Methylprednisolone			Potential for increased risk of adrenal insufficiency and Cushing's syndrome	Red: Avoid combination	Do not coadminister: Potential for increased levels of methylprednisolone	Do not coadminister if methylprednisolone being used for local injection.	Prednisone, prednisolone
5824	Elvitegravir Ranolazine 209	Elvitegravir			Ranolazine			Potential for increased risk of ranolazine adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine	Contraindicated. Use alternative agents.
5840	Elvitegravir Betamethasone 225	Elvitegravir			Betamethasone			Potential for increased risk of adrenal insufficiency and Cushing's syndrome	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Do not coadminister if betamethasone used for local injection.	Prednisone, prednisolone
5856	Elvitegravir Dronabinol 241	Elvitegravir			Dronabinol			Potential for increased risk of dronabinol adverse effects (e.g. sedation)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering initiate dronabinol at lowest dose. Monitor response and titrate according to efficacy and adverse effects.
5872	Elvitegravir Amlodipine 257	Elvitegravir			Amlodipine			Potential for increased risk of amlodopine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor ECG
5888	Elvitegravir Posaconazole 273	Elvitegravir			Posaconazole				Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor posaconazole concentrations.
5745	Elvitegravir Naloxone 130	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Not reported	Naloxone	4-6 mg once daily	Cmax and AUC decrease 28%	Potential reduced efficacy of naloxone	Green: Administer standard doses	Administer standard doses
5761	Elvitegravir Calcium carbonate 146	Elvitegravir			Calcium carbonate			Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased elvitegravir efficacy	Separate elvitegravir / cobicistat from medications containing polyvalent cations by at least 2 hours.
5777	Elvitegravir Doxazosin 162	Elvitegravir			Doxazosin			Potential for increased risk of doxazosin adverse effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of doxazosin	Initiate low dose doxazosin and titrate dose according to efficacy and adverse effects.
5793	Elvitegravir Lamotrigine 178	Elvitegravir			Lamotrigine			Potential for increased anticonvulsant effects	Green: Administer standard doses	Administer standard doses	Frequent clinical monitoring is recommended
5809	Elvitegravir Alprazolam 194	Elvitegravir			Alprazolam			Potential for increased alprazolam effects (e.g. sedation, altered mental status, respiratory depression)	Red: Avoid combination	Do not coadminister: Potential for increased levels of midazolam	Coadministration of EVG with oral midazolam is contraindicated. Parenteral midazolam can be used with caution when given as a single dose in a closely monitored situation for procedural sedation.	Lorazepam, Oxazepam, Temazepam
5825	Elvitegravir Salmeterol 210	Elvitegravir			Salmeterol			Increased risk of cardiovascular adverse events (e.g. QT prolongation, palpitations, sinus tachycardia)	Red: Avoid combination	Do not coadminister: Potential for increased levels of salmeterol	Use alternative agents
5841	Elvitegravir Quinidine 226	Elvitegravir			Quinidine			Potential for increased risk of quinidine adverse effects (e.g. cardiac arrhythmias)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	If coadministering use with caution and monitor for quinidine toxicity. Consider therapeutic drug monitoring and ECG
5857	Elvitegravir Escitalopram 242	Elvitegravir			Escitalopram			Potential increase in SSRI adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering initiate escitalopram therapy with lowest dose. Monitor escitalopram response and titrate according to efficacy and adverse effects	Sertraline
5873	Elvitegravir Diltiazem 258	Elvitegravir			Diltiazem			Potential for increased risk of diltiazem adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor ECG
5889	Elvitegravir Fentanyl 274	Elvitegravir			Fentanyl			Potential for increased risk of sedation and respiratory depression	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, titrate carefully and monitor for sedation and respiratory depression
5746	Elvitegravir Sertraline 131	Elvitegravir	150 mg elvitegravir / 150 mg cobicistat once daily	Cmax decreased 12%; AUC decreased 6%	Sertraline	50 mg single dose	Cmax increased 14%; AUC decreased 7%		Green: Administer standard doses	Administer standard doses
5762	Elvitegravir Calcium carbonate 147	Elvitegravir			Calcium carbonate			Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid decreased elvitegravir efficacy	Separate elvitegravir / cobicistat from medications containing polyvalent cations by at least 2 hours.
5778	Elvitegravir Doxepin 163	Elvitegravir			Doxepin			Potential for increased risk of doxepin adverse effects (e.g. sedation)	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of doxepin	If coadministering initiate doxepin at lowest dose. Monitor response and titrate according to efficacy and adverse effects.
5794	Elvitegravir Clonazepam 179	Elvitegravir			Clonazepam			Potential for increased clonazepam effects (e.g. sedation, respiratory depression)	Green: Administer standard doses	Administer standard doses	Frequent clinical monitoring is recommended	Lorazepam, Oxazepam, Temazepam
5810	Elvitegravir Midazolam 195	Elvitegravir			Midazolam			Potential for increased midazolam effects (e.g. prolonged sedation, altered mental status, respiratory depression)	Red: Avoid combination	Do not coadminister: Potential for increased levels of midazolam	Co-administration of oral midazolam is contraindicated. Parenteral midazolam can be used with caution when given as a single dose in a closely monitored situation for procedural sedation.	Lorazepam, Oxazepam, Temazepam
5826	Elvitegravir Suvorexant 211	Elvitegravir			Suvorexant			Potential for increased suvorexant adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of suvorexant	Use alternative agents
5842	Elvitegravir Tamsulosin 227	Elvitegravir			Tamsulosin			Potential for increased tamulosin adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternate agents. If coadministering, use with caution and monitor for tamulosin related adverse effects
5858	Elvitegravir Citalopram 243	Elvitegravir			Citalopram			Potential for increased SSRI adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering initiate therapy with lowest citalopram dose. Monitor citalopram response and titrate dose according to efficacy and adverse effects.	Sertraline
5874	Elvitegravir Felodipine 259	Elvitegravir			Felodipine			Potential for increased risk of felodipine adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering use with caution and monitor ECG
5890	Elvitegravir Tramadol 275	Elvitegravir			Tramadol			Potential for increased sedation	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Initiate tramadol at lowest dose. If initiating elvitegravir / cobicistat, tramadol may require a dose reduction - monitor for efficacy and adverse effects to titrate.
5907	Raltegravir ATV 292	Raltegravir	400 mg BID	Raltegravir AUC increased 41%; Cmax increased 24%; Cmin increased 77%	Atazanavir	300 mg with 100 mg ritonavir daily		Potential for increased raltegravir effects	Green: Administer standard doses	Administer standard doses
5923	Raltegravir RTV 308	Raltegravir	400 mg x 1	Raltegravir AUC decreased 16%; Cmax decreased 24%	Ritonavir	100 mg BID	Not reported		Green: Administer standard doses	Administer standard doses
5939	Raltegravir Oxcarbazepine 324	Raltegravir			Oxcarbazepine			Potential decrease in antiretroviral efficacy	Orange: Minimal data to guide interaction	Do not coadminister: Potential for reduced levels of raltegravir	Consider using alternative agents	Levitiracetam
5908	Raltegravir ATV 293	Raltegravir	100 mg x 1	Raltegravir AUC increased 72%; Cmax increased 53%; Cmin increased 95%	Atazanavir	400 mg daily		Potential for increased raltegravir effects	Green: Administer standard doses	Administer standard doses
5924	Raltegravir ETR 309	Raltegravir	400 mg BID	Raltegravir AUC decreased 10%; Cmin decreased 34%	Etravirine	200 mg BID	Not reported		Green: Administer standard doses	Administer standard doses
5940	Raltegravir Valproic acid 325	Raltegravir			Valproic Acid				Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for raltegravir efficacy	Levitiracetam
5909	Raltegravir Calcium carbonate 294	Raltegravir	400 mg BID	Raltegravir AUC decreased 55%; Cmin decreased 32%	Calcium carbonate	3000 mg single dose	Not reported		Green: Administer standard doses	Administer standard doses		H2-receptor antagonists
5925	Raltegravir ATV 310	Raltegravir	400 mg BID	RAL AUC no significant change	Atazanavir	300 mg BID	Not reported		Green: Administer standard doses	Administer standard doses
5910	Raltegravir Famotidine 295	Raltegravir	400 mg BID	Raltegravir AUC increased 45%; Cmax increased 60%	Famotidine	20 mg daily given 2 hours before raltegravir			Green: Administer standard doses	Administer standard doses
5926	Raltegravir G/P 311	Raltegravir	400 mg BID	Raltegravir AUC increased 47%; Cmin increased 164%	Glecaprevir / Pibrentasvir	300 / 120 mg daily	Not reported		Green: Administer standard doses	Administer standard doses
5911	Raltegravir Omeprazole 296	Raltegravir	400 mg Q12H	Raltegravir AUC increased 212%; Cmin increased 46%; Cmax increased 315%	Omeprazole	20 mg daily x 4 days			Green: Administer standard doses	Administer standard doses
5927	Raltegravir SOF/VEL 312	Raltegravir	400 mg BID	Raltegravir Cmin increased 8%; AUC increased 5%.	Sofosbuvir / Velpatasvir	400 mg / 100 mg	Not reported		Green: Administer standard doses	Administer standard doses
5896	Raltegravir RIF 281	Raltegravir	400 mg x 1	Raltegravir AUC decreased 40%; Cmax decreased 38%; Cmin decreased 61%	Rifampin	600 mg daily	Not reported	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.	Rifabutin
5912	Raltegravir Omeprazole 297	Raltegravir	400 mg BID	Raltegravir AUC increased 39%; Cmax increased 50%; Cmin increased 24%	Omeprazole	20 mg daily	Not reported		Green: Administer standard doses	Administer standard doses
5928	Raltegravir SOF 313	Raltegravir	400 mg daily	No significant change	Sofosbuvir	400 mg x 1	Sofosbuvir Cmax decreased 43%; AUC decreased 27%		Green: Administer standard doses	Administer standard doses
5897	Raltegravir RIF 282	Raltegravir	800 mg BID	Raltegravir AUC increased 27%; Cmax increased 62%; Cmin decreased 53% (all compared to raltegravir 400 mg BID)	Rifampin	600 mg daily	Not reported	Potential decrease in antiretroviral efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.	Rifabutin
5913	Raltegravir Ginkgo biloba 298	Raltegravir	400 mg x 1	No significant change	Ginkgo biloba	120 mg BID	Ginkgo biloba AUC increased 21%; Cmax increased 44%		Green: Administer standard doses	Administer standard doses
5929	Raltegravir RPV 314	Raltegravir	400 mg BID	Raltegravir Cmin increased 27%	Rilpivirine	25 mg daily			Green: Administer standard doses	Administer standard doses
5898	Raltegravir RIF 283	Raltegravir	800 mg Q12H	Raltegravir AUC increased 27%; Cmin decreased 53%; Cmax increased 62% (compared to 400 mg raltegravir Q12H when given alone)	Rifampin	600 mg daily			Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of raltegravir	Dose raltegravir 800 mg orally twice daily. Do not coadminister raltegravir 1200 mg once daily with rifampin.	Rifabutin
5914	Raltegravir ETR 299	Raltegravir	400 mg	Not reported	Etravirine	200 mg	Etravirine AUC increased 10%, Cmin increased 17%		Green: Administer standard doses	Administer standard doses